Natural product-based therapy for B-cell cancer: Luteolin suppresses the expression of FOXP1 and inhibits Wnt/β-catenin signalling via up regulation of its target gene, 06/February/20145, 22.49

Natural product-based therapy for B-cell cancer: Luteolin suppresses the expression of FOXP1 and inhibits Wnt/β-catenin signalling via up regulation of its target gene, 06/February/20145, 22.49

Natural product-based therapy for B-cell cancer: Luteolin suppresses the expression of FOXP1 and inhibits Wnt/β-catenin signalling via up regulation of its target gene, 06/February/20145, 22.49 150 150

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Natural product-based therapy for B-cell cancer: Luteolin suppresses the expression of FOXP1 and inhibits Wnt/β-catenin signalling via up regulation of its target gene, 06/February/20145, 22.48, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests, for the first time, that Luteolin, by increasing the expression of its target gene, it may inhibit the expression of FOXP1. Thereby, it may inhibit Wnt/β-catenin signalling that promotes tumor B-cell proliferation. Thus, pharmacological formulations encompassing “Luteolin or its analogues”  can be used to inhibit B-cell cancer

Amount: $ 300

Undisclosed information: How Luteolin suppresses the expression of FoxP1.

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation